Literature DB >> 647466

Orbital extension of retinoblastoma: a clinicopathological study.

J Rootman, R M Ellsworth, J Hofbauer, D Kitchen.   

Abstract

We have studied all cases of orbital extension of retinoblastomas at the Edward S. Harkness Eye Institute in New York since 1925. Only 9.4% of the patients lived more than 2 years after diagnosis. Orbital retinoblastoma is frequently associated with systemic metastases. We emphasize the significance of massive choroidal involvement and periemissarial extension. Careful handling of the enucleation specimen at the time of surgery and during histologic preparation is important to avoid cell spillage and artifacts. Treatment should be early, multidisciplinary and include adjuvant chemotherapy.

Entities:  

Mesh:

Year:  1978        PMID: 647466

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  5 in total

1.  Histopathologic grading of anaplasia in retinoblastoma.

Authors:  Pia R Mendoza; Charles S Specht; G Baker Hubbard; Jill R Wells; Michael J Lynn; Qing Zhang; Jun Kong; Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2014-12-19       Impact factor: 5.258

2.  Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors.

Authors:  C L Shields; J A Shields; K A Baez; J Cater; P V De Potter
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

3.  Orbital retinoblastoma: Present status and future challenges - A review.

Authors:  Mohammad J Ali; Santosh G Honavar; Vijay A P Reddy
Journal:  Saudi J Ophthalmol       Date:  2010-10-13

4.  Orbital Pseudocellulitis: A Retinoblastoma-Associated Masquerade Syndrome.

Authors:  Francesco Martino; Maria Chiara Gelmi; Paolo Galluzzi; Sonia De Francesco; Clelia Miracco; Doris Hadjistilianou
Journal:  Ocul Oncol Pathol       Date:  2020-10-08

Review 5.  Orbital retinoblastoma: An update.

Authors:  Santosh G Honavar; Fairooz P Manjandavida; Vijay Anand P Reddy
Journal:  Indian J Ophthalmol       Date:  2017-06       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.